Maxim Group analyst Jason McCarthy maintained a Buy rating on Zevra Therapeutics (ZVRA – Research Report) yesterday and set a price target of $25.00.
Jason McCarthy has given his Buy rating due to a combination of factors that highlight Zevra Therapeutics’ strong financial position and strategic initiatives. The company recently announced a significant transaction involving the sale of its Rare Pediatric Disease Priority Review Voucher for $150 million, which is expected to close soon. This non-dilutive capital injection will bolster Zevra’s already robust balance sheet, enhancing their ability to support the commercial launches of Miplyffa for Niemann-Pick disease type C and Olpruva for urea cycle disorders.
Additionally, Zevra’s strategic focus on acquiring and licensing high-value assets aligns with their strong cash position, potentially enabling further growth through mergers and acquisitions. The recent FDA approval of Miplyffa, the first therapy for Niemann-Pick disease type C, positions the company to capture market share rapidly. Furthermore, the company’s valuation models, which include risk adjustments for their products, support a favorable outlook with a 12-month price target of $25.
According to TipRanks, McCarthy is an analyst with an average return of -19.0% and a 24.65% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Alterity Therapeutics, and Mesoblast.
In another report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $17.00 price target.